Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome Clinical Trial

Official title:

The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS).

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04347967
• Other study ID #: UMC119-06-ARDS-01
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: January 1, 2024
• Est. completion date: September 2025

Study information

• Verified date: November 2023
• Source: Meridigen Biotech Co., Ltd.
• Contact: Claire Liao
• Phone: +886-2-8978-7777
• Email: claire.liao[@]meridigen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS. UMC119-06 is ex vivo cultured human umbilical cord derived mensenchymal stem cells (hUC-MSCs) product which is intended for treatment of ARDS.

Description:

ARDS, a noncardiogenic respiratory disease, is characterized by progressive hypoxemia and respiratory distress, associated with explosive acute inflammation and alveolar edema. ARDS occurs in all age group of patients, where mortality rates increase in advancing age. In animal studies of ARDS, mensenchymal stem cells (MSCs) can attenuate lipopolysaccharides (LPS)-induced lung injury and pulmonary permeability edema through modulating the inflammatory. These findings show that MSCs may improve the clinical outcomes and prognosis of ARDS patient. Meridigen is developing UMC119-06, human umbilical cord-derived MSCs, for the treatment of ARDS. The purpose of this study is to assess the safety of UMC119-06 in patients with ARDS.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 18
• Est. completion date: September 2025
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects of age = 20 years and = 85 years.
• Subject has a diagnosis of moderate ARDS according to the Berlin definition of ARDS:

1. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph.

3. Hypoxemia: PaO2/ FiO2 > 100 mmHg to = 200 mmHg with PEEP = 5 cm H2O.

4. The time of onset of ARDS is when all of the specified ARDS criteria (2a-c) are met.

• Patient is intubated and mechanically ventilated.
• Subjects who had an onset of ARDS within 72 to 120 hours before start of treatment.
• Subjects with body weight between 40 to 90 kg.
• No decompensated heart failure.
• Subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided.
• Women of child-bearing potential should have a negative serum pregnancy test prior to

administration of investigational product., UNLESS they meet the following criteria:

1. Post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40 mIU/ml, OR;

2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy.

Exclusion Criteria:

• Greater than 72 hours since first meeting ARDS criteria per the Berlin definition.
• No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol.
• Expected life < 3 months from other cause than the respiratory failure.
• Subject is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support.
• Subjects with history of any type of malignancy.
• Major trauma in the prior 5 days.
• Subjects with major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within previous 14 days.
• Subjects who are pregnant (or plan to become pregnant within 3 months of investigational product treatment) or lactating.
• Subjects who have a significant concomitant illness as judged by principal investigator (PI).
• Subjects who have significant abnormal laboratory tests at screening:

1. >5 × upper limit of normal for alanine aminotransferase (ALT) or aspartate aminotransferase (AST).

2. >3 × upper limit of normal for total bilirubin.

3. >2 × upper limit of normal for serum creatinine.

• Subjects with known human immunodeficiency virus infection or who are immune compromised.
• Subjects who are unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation.
• Subjects with a history of severe allergic or anaphylactic reactions.
• Subjects with known allergy or hypersensitivity to any component of the formulation (normal saline and human serum albumin).
• Subjects who have participated in another clinical study of new investigational therapies or have received an investigational therapy within the 12 weeks before study drug administration.

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Biological:
• UMC119-06
Cohort 1: Low does of UMC119-06;Cohort 2: Medium does of UMC119- 06;Cohort 3: High does of UMC119-06

Locations

Country	Name	City	State
Taiwan	Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare.	New Taipei City

Sponsors (1)

Lead Sponsor	Collaborator
Meridigen Biotech Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence and frequency of adverse events related to administration of UMC119-06.	Incidence of Treatment-Emergent Adverse Events (TEAEs). Incidence of withdrawals due to AEs.	3 months from the day of administration
Secondary	Changes in mortality status	Improvement in mortality status.	15 months from the day of administration.
Secondary	Ventilator Free Days (VFD)	Improvement in clinical function as assessed by Ventilator Free Days (VFD).	28 days from the day of administration
Secondary	Change in Oxygenation Index (OI)	Improvement in clinical function as assessed by change in Oxygenation Index (OI).	7 days or discharge from ICU after the day of administration
Secondary	Change in Lung Injury Score (LIS)	Improvement in clinical function as assessed by change in Lung Injury Score (LIS), 0-16 points, severity increasing with higher points.	7 days or discharge from ICU after the day of administration
Secondary	Change in positive end-expiratory pressure (PEEP)	Improvement in clinical function as assessed by change in positive end-expiratory pressure (PEEP).	7 days or discharge from ICU after the day of administration
Secondary	Change in Lung Static Compliance	Improvement in clinical function as assessed by change in Lung Static Compliance	7 days or discharge from ICU after the day of administration
Secondary	Change in acute physiology and chronic health evaluation score (APACHE II)	Improvement in clinical function as assessed by change in acute physiology and chronic health evaluation score (APACHE II), higher scores correspond to more severe disease and a higher risk of death.	7 days from the day of administration